Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Oct 09, 2023 6:27pm
193 Views
Post# 35676252

RE:RE:RE:RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker Mirati

RE:RE:RE:RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker MiratiLike I said, I welcome other thoughts, either bellow or above.
my min $1billion , max $5 billion.

My " opinion":was backed with reasonable comparable evidence.
name calling?
Not sure your motivation.
im a long term shareholder & want to see as much $$$ return as possible.
Keeping things real?
at present state.
meaning as of right now, North of $5 billion would not be justified.
add- on an accelerated approval for Pancrearic cancer....as I mentioned previously.
That would make Pela/ Roche combo a blockbuster drug.
THEN, pick a number.
In the wait time. We can wish, dream, hope, want....all we can.
The reality will be science & business based.
1. what can Pela do in a FDA approved market.
2. what will that market be worth, to the aquiring pharma.
Until #1 is answered, everything  else is speculation.

<< Previous
Bullboard Posts
Next >>